Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorders
Award amount
$640,354Program and phase
SBIR · Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- UNITED STATE DRUG TESTING LABORATORIES, INC.
- Proposal award date
- 2017-09-14
- Contract end date
- 2019-08-31
- UEI
- XJGQSD827RC5
- Solicitation number
- PA16-302
- Topic code
- 230
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Identification of Epigenetic Biomarkers Associated with Prenatal Exposure to Substances of Abuse
- Novel SET Antagonists for the Treatment of Chronic Myelogenous Leukemia
- Hair Ethyl Glucuronide as a Long Term Alcohol Biomarker
- Phosphatidylethanol as an Alcohol Biomarker in Neonatal Blood Spots
- Phosphatidylethanol as an Alcohol Biomarker in Umbilical Cord Tissue
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Title: Developing a novel drug for neurobehavioral deficits in FASD
- Developing a novel drug for neurobehavioral deficits in FASD
Research funding history
11 SBIR/STTR records share this UEI (1997–2021). Reported award amounts total $3,761,843. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services